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ABSTRACT 
Background: Hypertrophic cardiomyopathy (HCM) is associated with sudden cardiac death (SCD). 
Some studies have shown an association between risk of sudden death and left ventricular maximal 
wall thickness (MWT), but there are few data in patients with extreme hypertrophy. The aim of this 
study was to determine the relation between MWT and the risk of SCD. 
Methods and results: This is a multicentre, retrospective, longitudinal cohort study of 3673 adult 
(≥16 years) patients, previously used to develop and validate a risk prediction model for SCD (HCM 
Risk-SCD). There was an inverted U-shaped relation between MWT and the estimated 5 year risk of 
SCD. In patients with MWT≥35mm [n=47; mean age 33 years; 81% male] there was a single SCD 
end-point (annual rate 0.2%; 95% CI: 0.03, 1.60) and three additional cardiovascular events during a 
median follow-up of 9.5 years. Compared to patients with MWT≤14mm, those with MWT≥35mm did 
not have a higher risk for SCD (HR 0.22; 95% CI 0.03, 1.65), cardiovascular death (HR 0.66; 95% CI 
0.26, 1.67) or all-cause mortality (HR 0.73; 95% CI 0.32, 1.69). 
Conclusions: The risk of SCD has a complex, non-linear relationship to MWT. The 
pathophysiological mechanisms behind this observation require further study but ICD implantation 
should not be guided solely on the severity of left ventricular hypertrophy. 
 
KEYWORDS: hypertrophic cardiomyopathy; sudden cardiac death; implantable cardioverter 
defibrillator; risk prediction model 
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INTRODUCTION 
Hypertrophic cardiomyopathy (HCM) is an inherited myocardial disorder characterised by increased 
left ventricular wall thickness which is not solely explained by abnormal loading conditions.1 The 
clinical perception is that the more severe the hypertrophy, the higher is the risk of sudden cardiac 
death (SCD)2 and left ventricular maximal wall thickness (MWT) is one of several clinical features 
used to guide prophylactic implantable cardioverter defibrillator (ICD) therapy.1-3 However, patients 
at the most severe end of the hypertrophy spectrum are under-represented in clinical studies4,5 and 
their assumed high risk status is based on extrapolation of data from other patient subgroups. A recent 
multicentre study reported that patients with left MWT ≥35mm were not at higher risk of SCD 
compared to patients with lesser hypertrophy,6 echoing the findings of an earlier cohort study.7. The 
aim of this study was to examine the relation between MWT and the risk of SCD. 
METHODS 
Study design and overview 
This is a retrospective, multi-centre, longitudinal cohort study conducted by the Hypertrophic 
Cardiomyopathy Outcomes Investigators (www.HCMRisk.org). The relation of SCD risk and MWT 
was illustrated using the HCM Risk-SCD model,8 and survival analysis was used to examine how the 
observed SCD end-points compared to the risk estimates. The phenotype, genotype and outcomes of 
patients with extreme MWT (≥35mm) are described to corroborate the risk estimates and survival 
analysis. 
 
The study conforms to the principles of the Helsinki declaration. The sponsors of this study did not 
have a role in study design, data collection, analysis, and interpretation. COM, FJ, RO and PE had 
access to all data and final responsibility to submit the manuscript. The authors from each participating 
centre guarantee the integrity of data from their institution. All investigators have agreed to the 
manuscript as written. Author contributions can be found in the supplementary files. Patients at A 
Coruña University Hospital (Spain), Unit of Inherited Cardiovascular diseases at the 1st Department of 
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Cardiology (Athens), University Hospital Virgen de la Arrixaca (Spain), and Monaldi Hospital (Italy) 
provided written informed consent. The ethics committees at Heart Hospital (UK), and Institute of 
Cardiology at the University of Bologna (Italy) were informed, but approval was not required under 
local research governance arrangements. 
 
Study population and participating centres 
The study cohort consisted of consecutively evaluated patients with HCM from six European centres. 
HCM was defined as a maximum left ventricular wall thickness ≥15mm unexplained by abnormal 
loading conditions1 or in accordance with published criteria for the diagnosis in relatives of patients 
with unequivocal disease.9 All patients were ≥16 years of age, with no history of ventricular 
fibrillation or sustained ventricular tachycardia.  
 
A risk prediction model for SCD (HCM Risk-SCD) was previously derived from this retrospective, 
multi-centre longitudinal cohort study of 3675 patients using the Cox proportional hazards model and 
internally validated using bootstrapping. Univariable Cox regression models were fitted for each 
continuous predictor to test the assumption of linearity with the outcome. To develop the final risk 
model, multivariable Cox regression models were fitted with all predictors and quadratic terms for the 
continuous predictors where non-linearity was found. Of eight pre-specified predictors, age, MWT, 
left atrial diameter, left ventricular outflow tract gradient, family history of SCD, non-sustained 
ventricular tachycardia, and unexplained syncope were associated with SCD/appropriate ICD shocks 
at the 15% significance level. MWT was observed to have a nonlinear association with SCD and 
hence a quadratic term was included for this predictor. These predictors were included in the final 
model used to estimate individual probabilities of SCD at 5 years. Procedures for collecting clinical 
data, the detailed clinical characteristics of this cohort and the methods used to develop the risk model 
have been reported previously.8 Since the publication of HCM Risk-SCD, two patients (including one 
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affected by a SCD end-point) were found to have a metabolic disorder and were excluded from the 
current study. 
Study outcomes  
The primary study end-point was SCD defined as a composite of witnessed sudden cardiac death with 
or without documented ventricular fibrillation, death within one hour of new symptoms, nocturnal 
deaths with no antecedent history of worsening symptoms, aborted SCD or an appropriate ICD 
shock.10 
 
Secondary study end-points for exploratory analyses were as follows: 
a) Cardiovascular death defined as a composite of SCD, death from heart failure (death preceded by 
signs and/or symptoms of heart failure, including cardiogenic shock), stroke, pulmonary or peripheral 
arterial embolisation, death from a cardiac procedure or myocardial infarction, or orthotopic heart 
transplantation for end-stage heart failure, as previously described.10 
b) All-cause mortality defined as a composite of cardiovascular death (as defined above) and any 
other cause of death. 
General statistical methods 
All statistical analyses were carried out using STATA (versions 11 and 13). Variables are expressed 
as mean ± standard deviation (SD), median (25th percentile - 75th percentile) or counts and percentages 
as appropriate. Least squares linear regression was used to assess the relation of MWT groups to 
continuous variables. Chi-squared tests were used to assess the relation of MWT to categorical 
variables.11 The Bonferroni correction was applied as a multiple testing correction strategy. 
MWT as a continuous variable and the estimated probability of SCD at 5 years 
The relation between MWT as a continuous variable (mm) and 5-year SCD risk was examined 
graphically. The risk was calculated using the HCM Risk-SCD model8 for all MWT values observed 
in the study (ranging from minimum to maximum), with continuous variables set to their mean value 
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for the study cohort and dichotomous variables set to 0 (absence) and 1 (presence) to show the effect 
on risk estimates.  
Statistical models examining the relation of MWT in 5mm subgroups to clinical outcomes 
In accordance to previous studies, outcomes were examined in 5mm MWT subgroups.4-6 The Cox 
proportional hazards model was used to examine SCD using the HCM Risk-SCD predictor variables.8 
The same variables were used in two additional Cox proportional hazards models to explore the 
relation of MWT to the secondary study outcomes (cardiovascular death and all-cause mortality). The 
follow-up time for each patient was calculated from the date of their first evaluation to the date of 
reaching the primary end-point, or death from another cause, or to the date of their most recent 
evaluation. The annual event rate was calculated by dividing the number of patients reaching the 
endpoint by the total follow-up period for that end-point. The cumulative probability for the 
occurrence of an outcome was estimated using the Kaplan-Meier method. Data were assumed to be 
missing at random and values for the missing predictors were imputed using multiple imputation 
techniques based on chained equations as previously described.8 
Genetic data 
The cohort was not systematically tested for mutations of sarcomere myofilament genes. The results 
of ad hoc genetic testing of patients with extreme hypertrophy are presented. In the absence of 
evidence to the contrary (e.g. lack of co-segregation with disease in a family), variants previously 
reported in the literature as mutations were considered disease causing. The pathogenicity of 
unreported sequence variants was determined by in silico prediction methods and where possible co-
segregation analysis. 
RESULTS 
Baseline clinical characteristics 
The study population consisted of 3673 patients with mean MWT 19.6±5mm (minimum: 7mm 
[diagnosis of HCM on the basis of familial criteria]; maximum: 43mm; figure 1). Thirteen patients 
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(0.35%) had missing MWT data at baseline (patterns of missing data have been reported elsewhere8). 
The baseline clinical characteristics are shown in table 1. The associations of baseline clinical 
characteristics to MWT are illustrated in figure 2 (continuous variables) and figure 3 (categorical 
variables).  
Follow-up characteristics and clinical outcomes in the entire cohort 
The 3673 patients were followed-up for a total of 24,298 patient-years (median 5.7 (2.8 - 9.2) years). 
The annual rate of SCD end-points was 0.8% (95% CI 0.7, 0.9) with a 5-year cumulative incidence of 
3.7% (95% CI 3.1, 4.5). The annual rate of cardiovascular death was 1.7% (95% CI 1.5, 1.9) with a 5-
year cumulative incidence of 7.0% (95% CI 6.1, 8.1). Cardiovascular deaths (n=414) consisted of 197 
SCD events, 91 heart failure deaths, 47 cardiac transplants and 79 other cardiac deaths. The annual 
all-cause mortality (556 end-points) was 2.3% (95% CI 2.1, 2.5) with a 5-year cumulative incidence 
of 9.0% (95% CI 8.1, 10.1). 
MWT as a continuous variable and the estimated probability of SCD at 5 years 
The estimated risk of SCD at 5 years had a non-linear relation to MWT as shown in figure 4. The 
inverted U-shape of this relation means that the estimated risk of SCD increases with worsening 
hypertrophy to reach plateau and declines thereafter. The inverted U-shaped curve becomes more 
pronounced with increases in prognostic index i.e. with higher risk of SCD. This suggests that, for a 
specified change in MWT there appears to be a variable change both in the magnitude and direction of 
SCD risk depending on other risk predictors e.g. an increase in MWT from 20 to 25mm is associated 
with a higher increase in the risk of SCD when other high risk features are present (high prognostic 
index). 
Relation of MWT in 5mm subgroups to SCD and additional exploratory analyses 
The Kaplan-Meier curves showing the cumulative incidence of the SCD end-point, cardiovascular 
deaths, and all-cause mortality in 5mm MWT groups are shown in figure 5. The effect of 5mm 
increments in MWT on the primary study outcome (SCD) and the secondary exploratory outcomes 
(cardiovascular deaths and all-cause mortality) was examined in three multivariable Cox proportional 
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hazards models shown in table 2. Compared to HCM patients with MWT≤14mm, patients with 
MWT≥35mm did not have a significantly higher risk for SCD, cardiovascular death or all-cause 
mortality.  
Follow-up characteristics and clinical outcomes in patients with extreme hypertrophy 
The 47 patients (1% of the cohort) with MWT≥35mm had longer follow-up (median 9.5 (4.8 - 13.3) 
years) than the rest of the cohort (median 5.6 (2.8 - 9.2) years). During a total of 445 patient-years, 
four patients with MWT≥35mm died from cardiovascular causes (one suddenly, two from heart 
failure and one from systemic embolisation; table 3). All observed cardiovascular deaths in patients 
with MWT≥35mm occurred beyond 5 years of follow-up. The annual rate of the SCD end-point was 
0.2% (95% CI 0.03, 1.60) with a 10-year cumulative incidence of 3.0% (95% CI 0.4, 20.0). The 
annual rate of cardiovascular death was 0.9% (95% CI 0.3, 2.6) with a 10-year cumulative incidence 
of 10.0% (95% CI 0.3, 29.0). A single patient with MWT≥35mm died from non-cardiac causes 
(complications of viral respiratory tract infection after 4.8 years of follow-up). The annual all-cause 
mortality rate was 1.1% (95% CI 0.5, 2.7) with a 10-year cumulative incidence of 12.0% (95% CI 0.5, 
31.0). 
Sarcomeric protein gene mutations in patients with extreme hypertrophy 
Genetic testing was carried out in 37 (79%) patients with MWT≥35mm. Sarcomeric protein gene 
mutations were detected in 16 patients (43%). Mutations in myosin-binding protein C (MYBPC3) 
and/or β-myosin heavy chain (MYH7) mutations were detected in 13 (81%) of the 16 mutation 
positive patients and one patient (6%) was double heterozygote. The sarcomeric protein gene 
mutations and clinical characteristics of the 16 genotype positive patients are shown in supplementary 
table 2. Variants of unknown significance are also shown in the supplementary data. Of the remaining 
31 patients (21 mutation-negative and 10 not genetically tested), 2 (6%) received a pacemaker during 
follow-up and none had evidence of pre-excitation. The baseline clinical characteristics of mutation-
positive and mutation-negative patients, and patients who were not genetically tested are shown in 
supplementary table 3. 
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DISCUSSION 
Until very recently, it was assumed that the risk of SCD in patients with HCM increased in direct 
proportion to the severity of hypertrophy.2,4,5 This study shows that the relationship between SCD risk 
and MWT is more complex than previously thought in that risk increases with worsening hypertrophy 
to reach plateau and declines thereafter. Contrary to received opinion, the incidence of SCD in 
patients with extreme hypertrophy may not be very high in the absence of other clinical risk factors. 
 
There is no clear explanation for the inverted U-shaped relation of MWT to SCD. All patients with 
HCM have the structural substrate for ventricular arrhythmias. Disarray and cardiac hypertrophy 
support re-entry12 and arrhythmias are often triggered by premature ventricular ectopics.13 It is also 
likely that sustained ventricular arrhythmias are precipitated only when transient phenomena (e.g. 
myocardial ischemia secondary to left ventricular outflow tract obstruction) reduce the threshold for 
arrhythmogenesis.13,14 Patients at the extremes of the MWT spectrum may have a very high 
arrhythmia threshold or be less exposed to transient functional modulators. We cannot exclude the 
coexistence of other unknown protective factors that operate at the extremes of the MWT spectrum 
and confer a survival advantage. Advanced tissue characterisation techniques using CMR or PET may 
further our understanding of the arrhythmogenic substrate in HCM.15 
 
In this study patients with extreme hypertrophy experienced few clinical events despite longer follow-
up. These data are in keeping with the limited literature on hypertrophy of this severity. In one study 
of 30 patients with MWT≥35mm, there was only one SCD end-point after a mean follow-up of 6 
years (approximate event rate: 0.6%/year; 95% CI 0.08, 3.9).7 In a more recent multivariable analysis 
which examined the temporal association of unexplained syncope to SCD, 30 patients with 
MWT≥35mm were found to have a similar risk of SCD to patients with MWT≤10mm (hazard ratio: 
0.66; 95% CI 0.21, 17.87).6 In all published studies, the confidence intervals associated with the risk 
estimates are wide due to small numbers which is an inherent limitation when studying the extremes 
of the phenotypic spectrum.  
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Since 2003, international guidelines have considered MWT≥30mm as a risk factor for SCD,2,3 but the 
data to support this recommendation are conflicting (figure 6).4-6,10,16-24 In this context, our findings 
suggest that ICD implantation should not be based solely on the severity of left ventricular 
hypertrophy and that a more global SCD risk assessment which integrates other risk factors should be 
used. 
 
In this study the typical patient with MWT≥35mm was a young male and the prevalence of 
LVOTO≥50mmHg, non-sustained ventricular tachycardia, left atrial dilation, NYHA class III/IV and 
unexplained syncope was less than other MWT subgroups. The comparatively small left atrial size 
and good functional capacity in this subgroup may be related to the lower prevalence of significant 
left ventricular outflow tract obstruction.17,21,22 Even though most patients were <40 years of age, 
MWT≥35mm was not exclusively seen in young patients. The male preponderance is not unique to 
this patient subgroup, and may relate to sex hormone receptor gene variations, social factors or 
diagnostic bias. 25,26 
 
We hypothesised that the genetic substrate in patients with MWT≥35mm might differ from patients 
with lesser degrees of hypertrophy. However, the overall prevalence of sarcomeric protein gene 
mutations in patients with MWT≥35mm was comparable to that reported in recent pooled analysis of 
unselected cohorts of unrelated HCM patients and was similarly dominated byMYH7 and MYBPC3 
mutations.27 In addition, none of the observed mutations has been consistently linked with 
MWT≥35mm. Complex genotypes have been associated with severe hypertrophy,28-30 but this study 
shows that the reverse is not true as the majority of cases MWT≥35mm was not linked to a complex 
genotype. HCM with extreme MWT can be a feature of some glycogen storage diseases and it is 
conceivable that some patients had undiagnosed metabolic disorders. However, the lack of 
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electrocardiographic evidence of pre-excitation, the low prevalence of permanent pacemaker 
implantation and the relatively benign natural history make diseases such as Danon and PRKAG2 
related cardiomyopathy31 unlikely causes for the phenotype in mutation-negative patients. It is more 
likely that other genomic and environmental modifiers are responsible for the severe phenotypic 
expression. 
Limitations 
Even though this is the largest cohort of HCM patients with MWT≥35mm, the number of patients is 
still small, reflecting the low prevalence of this phenotype. The findings of this study are limited to 
patients without a history of aborted SCD and exclusion of patients with MWT≥35mm and a previous 
history of aborted SCD could give the impression of better prognosis. However, patients with 
MWT≥35mm are also scarce in previously published cohorts with aborted SCD32,33 and this is an 
unlikely explanation for the observations of this study. The findings of this study should not be 
extrapolated to pediatric (<16 years) patients as they were excluded from the study. Furthermore, 
HCM Risk-SCD estimates use MWT as the sole measure of left ventricular hypertrophy, and the 
impact of the septal morphology34 and/or extent of hypertrophy5 on SCD risk was not examined. 
CONCLUSIONS 
The risk of SCD has a complex, non-linear relation to MWT in patients with HCM. Patients with 
MWT≥35mm may have a relatively good prognosis from SCD despite the extreme severity of 
hypertrophy. The pathophysiological mechanisms behind this observation require further study but 
ICD implantation should not be guided solely on the severity of left ventricular hypertrophy. 
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TABLE 1: Clinical characteristics at baseline evaluation 
Baseline characteristic Study 
population 
Maximal LV 
wall thickness 
≥35mm 
Number of patients 3673 47 
Male 2347 (64%) 38 (81%) 
Age; years 48±16 33±14* 
NYHA III/IV 426 (12%) 3 (7%) 
Myectomy 34 (1%) 0 
Alcohol septal ablation 10 (0.3%) 0 
Amiodarone 468 (13%) 7 (15%) 
ICD† 42 (1%) 3 (6%) 
NSVT 633 (20%) 13 (29%) 
LA diameter; mm 44±8 45±7 
LVOTGmax; mmHg 12 (5-49) 16 (8-43) 
LVOTGmax≥50 mmHg 891 (25%) 11 (24%) 
LVedd; mm 45±7 40±6 
FS; % 41±9 47±11 
FHSCD 884 (24%) 15 (32%) 
Unexplained syncope 506 (14%) 4 (9%) 
LV: Left ventricular, NYHA: New York Heart Association, ICD: implantable cardioverter 
defibrillator, AF: Atrial fibrillation, NSVT: non-sustained ventricular tachycardia, LA: left atrium, 
LVOTG: left ventricular outflow tract gradient at rest or Valsalva, LVedd: left ventricular end 
diastolic dimension, MWT: maximal wall thickness, FS: fractional shortening, FHSCD: family 
history of sudden cardiac death, SCD: sudden cardiac death. 
*Age range: minimum 17.2 years, maximum: 77.3years; Interquartile range: 21.8-41.3 years 
† During the study period, a total of 558 (15%) patients were treated with an ICD 
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TABLE 2: The risk of cardiovascular outcomes and maximal wall thickness in 5mm groups 
 Primary outcome Exploratory analyses 
Sudden cardiac death Cardiac death/transplant All-cause mortality 
Variable Hazard Ratio p-value 95% CI Hazard Ratio p-value 95% CI Hazard Ratio p-value 95% CI 
M
a
xi
m
a
l 
w
a
ll
 t
h
ic
kn
es
s 
≤14mm Baseline group for comparison Baseline group for comparison Baseline group for comparison 
15-19mm 0.93 
0.02 
0.56, 1.54 0.82 
0.047 
0.59, 1.13 0.78 
0.02 
0.59, 1.03 
20-24mm 1.09 0.66, 1.81 0.90 0.65, 1.25 0.93 0.70, 1.23 
25-29mm 1.21 0.69, 2.13 0.99 0.68, 1.46 1.04 0.74, 1.44 
30-34mm 2.13 1.17, 3.89 1.56 0.99, 2.45 1.45 0.96, 2.19 
≥35mm 0.22 0.03, 1.65 0.66 0.26, 1.67 0.73 0.32, 1.69 
Age (years) 0.98 0.001 0.97, 0.99 1.01 <0.001 1.01, 1.02 1.03 <0.001 1.02, 1.04 
LA diameter (mm) 1.03 0.004 1.01, 1.05 1.05 <0.001 1.04, 1.06 1.04 <0.001 1.03, 1.05 
LVOTGmax (mmHg) 1.01 0.007 1.001, 1.01 1.001 0.470 0.998, 1.004 1.001 0.452 0.999, 1.003 
FHSCD 1.58 0.003 1.17, 2.12 1.27 0.033 1.02, 1.58 1.19 0.081 0.98, 1.45 
NSVT 2.44 <0.001 1.74, 3.42 1.83 <0.001 1.43, 2.33 1.48 <0.001 1.20, 1.83 
Unexplained syncope 1.99 <0.001 1.44, 2.74 1.58 <0.001 1.24, 2.02 1.54 <0.001 1.24, 1.91 
LA: left atrium, LVOTG: left ventricular outflow tract gradient at rest or Valsalva, FHSCD: family history of sudden cardiac death, NSVT: non-sustained ventricular 
tachycardia. The number of end-points per 5mm subgroup is shown in supplementary table 1. 
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Table 3: Baseline clinical characteristics of patients with maximal left ventricular wall thickness ≥35mm experiencing cardiovascular end-points  
Age 
(years) 
Sex NSVT MWT 
(mm) 
LVedd 
(mm) 
LA 
(mm) 
LVOTg 
(mmHg) 
FHSCD Unexplained 
syncope 
Follow-up 
(years) 
Mutation CVS end-point 
24 Male No 36 40 44 8 No No 9.7 MYH7: R723C Heart failure 
29 Male No 37 47 45 55 Yes Yes 7.3 None detected SCD 
49 Male Yes 37 30 42 19 No No 17.5 Not tested Systemic embolus 
77 Female No 37 37 50 66 Yes No 8.1 MYH7: I736T and 
TNNT2: A28V 
Heart failure 
NSVT: non-sustained ventricular tachycardia, LA: left atrium, LVOTg: left ventricular outflow tract gradient at rest or Valsalva, LVedd: left ventricular end diastolic dimension, 
MWT: maximal wall thickness, FS: fractional shortening, FHSCD: family history of sudden cardiac death, SCD: sudden cardiac death, CVS: cardiovascular death. All patients 
were in NYHA 1-2, and in sinus rhythm at baseline evaluation. 
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FIGURE LEGENDS 
FIGURE 1: The distribution of maximal wall thickness in the study cohort 
Patients with MWT<15mm were diagnosed on the basis of familial disease.9 
 
FIGURE 2: Relation of maximal left ventricular wall thickness to age and left atrial diameter 
Mean age (years) and left atrial diameter (mm) with 95% CI, for each 5mm MWT subgroup are shown 
in panel A and B respectively. The p values relate to linear regression. 
 
FIGURE 3: The relation of baseline clinical characteristics to maximal left ventricular wall 
thickness 
Proportions (shown on Y-axes) were used to examine the relation of male sex (panel A), NSVT (panel 
B), LVOTO ≥50mmHg (panel C), family history of SCD (panel D), NYHA III/IV (panel E) and 
unexplained syncope (panel F) to MWT. The graphs show the proportion for each MWT group, 95% 
intervals. A chi-squared test for trend was used,11 and the p value with the Bonferroni correction applied 
is shown. 
 
FIGURE 4: The relation of the estimated 5-year risk of SCD to maximal left ventricular wall 
thickness. 
The risk of SCD at 5-years was calculated using HCM Risk-SCD with the following predictors kept 
constant to the cohort mean: age=48years, maximal left ventricular outflow tract gradient=12mmHg, 
left atrial diameter=44mm.The four curves represent the estimated risk with all possible combinations 
of NSVT and unexplained syncope, keeping family history of SCD=0. In all cases the risk of SCD 
increases up to a point and once a plateau is reached, the risk declines. The vertical reference lines 
represent the 1% and 99% centiles of MWT in this cohort. Variations in family history of SCD also 
showed the same pattern (plots not shown for clarity). 
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FIGURE 5: Kaplan-Meier curves showing the incidence of SCD end-points, cardiovascular death 
and all-cause mortality. 
Patients were classified in six 5mm groups on the basis of maximum wall thickness, in accordance to 
previous studies.4-6 Panel A shows the cumulative incidence for the SCD end-point. Panel B shows the 
cumulative incidence for cardiovascular death. Panel C shows the cumulative incidence for all-cause 
mortality. 
 
FIGURE 6: The risk of SCD and maximal wall thickness ≥30mm in previous survival analyses. 
In all studies the number of patients with MWT≥30mm is small, and there is no consistent independent 
association with SCD.4-6,10,16-24 The vertical reference line represents a hazard ratio of 1. 
.  
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FIGURE 1: The distribution of maximal wall thickness in the study cohort. 
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FIGURE 2: Relation of maximal left ventricular wall thickness to age and left atrial diameter 
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FIGURE 3: The association of baseline clinical characteristics and maximal left ventricular wall 
thickness 
A: Male sex     B: Non-sustained VT 
 
C: LVOTO≥50mmHg     D: Family history of SCD
 
E: NYHA III/IV    F: Unexplained syncope 
 
  
0
.1
.2
.3
.4
.5
.6
.7
.8
.9
1
P
ro
p
o
rt
io
n
 o
f 
m
a
le
s
<=14mm 15-19mm 20-24mm 25-29mm 30-34mm =>35mm
Maximal wall thickness
95% confidence intervals
p>0.1
0
.1
.2
.3
.4
.5
P
ro
p
o
rt
io
n
 w
it
h
 N
S
V
T
<=14mm 15-19mm 20-24mm 25-29mm 30-34mm =>35mm
Maximal wall thickness
95% confidence intervals
p<0.001
0
.1
.2
.3
.4
.5
P
ro
p
o
rt
io
n
 w
it
h
 L
V
O
T
O
 >
=
5
0
m
m
H
g
<=14mm 15-19mm 20-24mm 25-29mm 30-34mm =>35mm
Maximal wall thickness
95% confidence intervals
p<0.001
0
.1
.2
.3
.4
.5
P
ro
p
o
rt
io
n
 w
it
h
 f
a
m
ily
 h
is
to
ry
 o
f 
S
C
D
<=14mm 15-19mm 20-24mm 25-29mm 30-34mm =>35mm
Maximal wall thickness
95% confidence intervals
p=0.001
0
.1
.2
.3
.4
.5
P
ro
p
o
rt
io
n
 w
it
h
 N
Y
H
A
 I
II
/I
V
<=14mm 15-19mm 20-24mm 25-29mm 30-34mm =>35mm
Maximal wall thickness
95% confidence intervals
p=0.03
0
.1
.2
.3
.4
.5
P
ro
p
o
rt
io
n
 w
it
h
 u
n
e
x
p
la
in
e
d
 s
y
n
c
o
p
e
<=14mm 15-19mm 20-24mm 25-29mm 30-34mm =>35mm
Maximal wall thickness
95% confidence intervals
p=0.02
 P
ag
e2
7
 
FIGURE 4: The relation of the estimated 5-year risk of SCD to maximal left ventricular wall 
thickness. 
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FIGURE 5: Kaplan-Meier curves showing the cumulative incidence of SCD end-points, cardiovascular death and all-cause mortality 
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FIGURE 6: The risk of SCD and maximal wall thickness ≥30mm in previous survival analyses. 
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